Evidence map›Paper›PMID 29372470›Full record

Trial reportClinical and experimental nephrology2018

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Takashi Wada, Tatsuo Hosoya, Daisuke Honda, Ryusuke Sakamoto, Kazutaka Narita, Tomomitsu Sasaki, Daisuke Okui, Kenjiro Kimura

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 6 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Takashi Wada *Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan.
Tatsuo Hosoya *Department of Pathophysiology and Therapy in Chronic Kidney Disease, Jikei University School of Medicine, Tokyo, Japan.
Daisuke HondaDrug Development Center, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Aichi, Japan. d_honda@skk-net.com.ORCID http://orcid.org/0000-0001-5624-7553
Ryusuke SakamotoR&D Strategy Center, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Aichi, Japan.
Kazutaka NaritaDrug Development Center, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Aichi, Japan.
Tomomitsu SasakiMedical R&D Division, Fuji Yakuhin Co., Ltd., Saitama, Japan.
Daisuke OkuiMedical R&D Division, Fuji Yakuhin Co., Ltd., Saitama, Japan.
Kenjiro KimuraJCHO Tokyo Takanawa Hospital, Tokyo, Japan.
Riso Kagaku (Japan) · JPJikei University School of Medicine · JPKanazawa University · JPNGK Spark Plug (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperuricemia is supposed to be an independent risk factor for kidney dysfunction in diabetic patients. We attempted to examine the uric acid-lowering effect and the renoprotective effect of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia in this pilot study.

methodsThe study design was randomized, double-blind, placebo-controlled, parallel-group study. A total of 65 patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned to either the topiroxostat group or the placebo group. Topiroxostat (stepwise dosing from 40 to 160 mg/day) or matching placebo was administered BID for 28 weeks. The primary endpoint was a change in the urinary albumin-to-creatinine ratio in the first-morning-void urine sample. Secondary endpoints were changes in the estimated glomerular filtration rate and the serum uric acid level.

resultsAt 28 weeks, there was no significant difference in the percent change from baseline in the urinary albumin-to-creatinine ratio between the two groups (topiroxostat: 0 vs. placebo: 17%, p = 0.3206), but the changes in the estimated glomerular filtration rate (- 0.2 vs. - 4.0 mL/min/1.73 m

conclusionThese findings support that diabetic nephropathy combined with hyperuricemia may be associated with kidney dysfunctions. Topiroxostat provides strict control of the serum uric acid level preventing decline of eGFR in these patients.

Indexed as

AgedDiabetic NephropathiesDouble-Blind MethodFemaleGlomerular Filtration RateHumansHyperuricemiaMaleMiddle AgedNitrilesPilot ProjectsPyridinesTreatment OutcomeUric AcidXanthine DehydrogenaseFYX-051NitrilesPyridinesUric AcidXanthine DehydrogenaseAlbuminuriaDiabetic nephropathyFYX-051Glomerular filtration rateHyperuricemiaTopiroxostatXanthine oxidoreductase inhibitor

Identifiers

PMID29372470
OpenAlexW2789891715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.